In a prospective study conducted with Ga68-PSMA-11 PET/MR images of 9 prostate cancer patients without previous treatment, a heterogenous increase of PSMA uptake which was more evident in bone metastases (average of 77% increase in SUVmax value) was observed on 34 weeks after ADT [11]. This evidence concerns the gene FOLH1 and prostate carcinoma.